HCPCS Level II · Drugs administered other than oral method
J0151Injection, adenosine for diagnostic use, 1 mg (not to be used to report any adenosine phosphate compounds, instead use a9270)
Terminated 12/31/2014
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About J0151
J0151 is an HCPCS Level II code in the J series (drugs administered other than oral method), describing injection, adenosine for diagnostic use, 1 mg (not to be used to report any adenosine phosphate compounds, instead use a9270).
It was added to HCPCS effective 01/01/2014, and its current record took effect 01/01/2015.
It was terminated on 12/31/2014 and can't be billed for later dates of service.
Its Medicare coverage code is "C", meaning coverage is left to the Medicare contractor's judgment.
Details
- Short description
- Inj adenosine diag 1mg
- Date added
- 01/01/2014
- Action effective
- 01/01/2015
- Termination date
- 12/31/2014
- BETOS
- O1E
Related J01xx codes
- J0120Injection, tetracycline, up to 250 mg
- J0121Injection, omadacycline, 1 mg
- J0122Injection, eravacycline, 1 mg
- J0129Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
- J0130Injection abciximab, 10 mg
- J0131Injection, acetaminophen, not otherwise specified,10 mg
- J0132Injection, acetylcysteine, 100 mg
- J0133Injection, acyclovir, 5 mg
- J0134Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg
- J0136Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg
- J0137Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg
- J0138Injection, acetaminophen 10 mg and ibuprofen 3 mg
Common questions about J0151
Is HCPCS J0151 still valid?
- No. J0151 was terminated on 12/31/2014.
Does Medicare cover J0151?
- Its coverage code is "C": coverage is left to the Medicare contractor's judgment. Check the local coverage determination for your region.